Redeye comments on Inhalation Sciences’ Q3 2022 report. Q3 sales came in at SEK1.8m, 57% higher than the same period last year (SEK1.1m). However, we lower our sales expectations for 2022e, make minor changes from 2023e and increase our WACC. This results in a lower fair value range with a decreased base case from SEK23 to SEK20.

Link to the analysis